Fate Therapeutics, Inc.

NasdaqGM:FATE 주식 보고서

시가총액: US$276.7m

Fate Therapeutics 관리

관리 기준 확인 3/4

Fate Therapeutics CEO는 J. Wolchko, Dec2015 에 임명되었습니다 의 임기는 8.92 년입니다. 총 연간 보상은 $ 3.52M, 18.3% 로 구성됩니다. 18.3% 급여 및 81.7% 보너스(회사 주식 및 옵션 포함). 는 $ 665.74K 가치에 해당하는 회사 주식의 0.24% 직접 소유합니다. 665.74K. 경영진과 이사회의 평균 재임 기간은 각각 6.8 년과 13.8 년입니다.

주요 정보

J. Wolchko

최고 경영자

US$3.5m

총 보상

CEO 급여 비율18.3%
CEO 임기8.9yrs
CEO 소유권0.2%
경영진 평균 재임 기간6.8yrs
이사회 평균 재임 기간13.8yrs

최근 관리 업데이트

Recent updates

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Aug 21
Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Aug 11
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 23
Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Feb 16
Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Jan 26

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Dec 19
Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Sep 08
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Jun 07
Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

May 08
Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Apr 17
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Sep 22
Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Aug 30

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Jul 28

Fate Therapeutics names Brian Powl as chief commercial officer

Jun 30

Fate: Possible Speedy FDA Approval Process With RMAT Designation

Jun 03

We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Jun 02
We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Fate Therapeutics: Slowly Getting To An Attractive Position

Feb 21

We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Feb 01
We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

CEO 보상 분석

J. Wolchko 의 보수는 Fate Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$176m

Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$4mUS$645k

-US$161m

Sep 30 2023n/an/a

-US$173m

Jun 30 2023n/an/a

-US$212m

Mar 31 2023n/an/a

-US$235m

Dec 31 2022US$8mUS$645k

-US$282m

Sep 30 2022n/an/a

-US$294m

Jun 30 2022n/an/a

-US$254m

Mar 31 2022n/an/a

-US$233m

Dec 31 2021US$12mUS$610k

-US$212m

Sep 30 2021n/an/a

-US$197m

Jun 30 2021n/an/a

-US$212m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$6mUS$570k

-US$173m

Sep 30 2020n/an/a

-US$149m

Jun 30 2020n/an/a

-US$117m

Mar 31 2020n/an/a

-US$112m

Dec 31 2019US$11mUS$540k

-US$98m

Sep 30 2019n/an/a

-US$86m

Jun 30 2019n/an/a

-US$76m

Mar 31 2019n/an/a

-US$72m

Dec 31 2018US$4mUS$516k

-US$67m

Sep 30 2018n/an/a

-US$63m

Jun 30 2018n/an/a

-US$57m

Mar 31 2018n/an/a

-US$47m

Dec 31 2017US$1mUS$480k

-US$43m

보상 대 시장: J. 의 총 보상 ($USD 3.52M )은 US 시장( $USD 1.48M ).

보상과 수익: J. 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

J. Wolchko (54 yo)

8.9yrs

테뉴어

US$3,522,750

보상

Mr. J. Scott Wolchko is the Founder of Fate Therapeutics, Inc. and has been its Chief Executive Officer and President since December 1, 2015 & serves as It's CFO and CAO since June 3, 2024. Mr. Wolchko ser...

리더십 팀

이름위치테뉴어보상소유권
J. Wolchko
Founder8.9yrsUS$3.52m0.24%
$ 665.7k
Cindy Tahl
Chief Legal & Compliance Officer and Corporate Secretary9.1yrsUS$2.82m0.053%
$ 146.4k
Bahram Valamehr
President of Research & Development6.8yrsUS$2.99m0.067%
$ 184.6k
Jerome Bressi
Chief Regulatory & Quality Officer2.8yrs데이터 없음0.24%
$ 671.1k
Andrew Henry
Senior Vice President of Clinical Operationsless than a year데이터 없음데이터 없음

6.8yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 관리: FATE 의 관리팀은 노련하고 경험 (평균 재직 기간 6.8 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
J. Wolchko
Founder9.1yrsUS$3.52m0.24%
$ 665.7k
William Rastetter
Independent Chairman13yrsUS$253.25k0.54%
$ 1.5m
John Mendlein
Independent Vice Chairman of the Board16.6yrsUS$218.33k0.27%
$ 756.3k
Robert Langer
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Bennett Shapiro
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Robert Epstein
Independent Director10.7yrsUS$228.25k0.010%
$ 27.5k
Stuart Orkin
Member of Scientific Advisory Board14.5yrs데이터 없음데이터 없음
Sui Huang
Member of Scientific Advisory Board14.5yrs데이터 없음데이터 없음
Timothy Coughlin
Independent Director11.3yrsUS$231.75k0.058%
$ 161.1k
Sean Morrison
Member of Scientific Advisory Board14.5yrs데이터 없음데이터 없음
Mark Krasnow
Member of Scientific Advisory Board14.5yrs데이터 없음데이터 없음
Karin Jooss
Independent Director5.7yrsUS$227.82k0.0086%
$ 23.9k

13.8yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: FATE 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 13.8 년).